Here, we investigate whether combining the hyperlipidemia drug class of cholesteryl ester transfer protein (CETP) inhibitors with the existing hyperglycemia treatment in sodium glucose transporter 2 (SGLT2) inhibitors is an effective strategy to improve glycemic control. Here, CETP is linked to hyperlipidemia.